SUMMARY
Methohexitone is a short acting barbiturate introduced into clinical anaesthesia in 1957 [1] . In contrast with thiopentone, it is characterized by rapid metabolism. However, the basis for its short action on induction of anaesthesia is its rapid distribution. While thiopentone is eliminated with a half-life of more than 6 h [2] [3] [4] , the elimination halflife of methohexitone is 2-4 h. The relatively rapid elimination of methohexitone is reflected in the high total body clearance of more than 800 ml min" 1 [5] [6] [7] . The relative contribution of the liver to the overall disposition in man, however, is not yet known. In order to clarify the site of disposition of methohexitone in man, we have studied patients who were undergoing cardiac surgery and receiving methohexitone for induction of anaesthesia.
PATIENTS AND METHODS
The study was approved by the local Ethics Committee and all patients gave written informed consent. We studied 10 male patients (table I) who were referred for elective coronary artery bypass surgery. All had involvement of one to three coronary vessels, but compensated ventricular function (ejection fraction range 0.71-0.46). Plasma concentrations of transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirubin, and prothrombin time were within normal limits and revealed no evidence of liver disease.
Current medication was continued until the day before the operation. Premedication consisted of flunitrazepam 2 mg orally on the evening before operation and 1.5 h before induction of anaesthesia.
Immediately after arrival of the patient in the operating theatre, a blank plasma sample was taken and a venous indocyanine green (ICG) infusion was started through a 14-gauge cannula in a forearm vein. After cannulation of a radial artery, a 12-gauge catheter was inserted through the right internal jugular vein and positioned under fluoroscopic control into a right hepatic vein. Hepatic venous oxygen saturation was measured to verify the position of the catheter during the investigation. A 12-gauge pulmonary artery thermodilution catheter was inserted by a brachial vein and wedge position was verified by the pressure curve. After measurement of cardiovascular variables at rest (MPI), anaesthesia was induced with methohexitone l.Smgkg" 1 , fentanyl 7ugkg~' and pancuronium O.lmgkg" 1 i.v. Patients' lungs were ventilated mechanically and normoventilation was verified by blood-gas analysis and measurement of end-expiratory carbon dioxide. Anaesthesia was maintained with a constant infusion of fentanyl 20 |ig min" 1 and nitrous oxide in oxygen with Fi Oi 0.5. Immediately after injection of methohexitone, hepatic plasma flow and cardiovascular variables were measured again for 15 min and arterial and hepatic venous samples were collected for measurement of plasma methohexitone concentrations (MPII). Before skin incision, a bolus dose of midazolam 5 mg was given to ensure hypnosis. The same measurements and blood samples as described for MPI and MPII were taken during sternotomy (MPIII).
Hepatic plasma flow was determined by the steady state infusion and extraction technique described by Bradley [8] using ICG as indicator. The infusion rate was 0.5 mg min" 1 throughout the whole period of investigation and the ICG infusion was started at least 30 min before the first measurements in order to allow time for the achievement of steady state conditions.
Three arterial and three hepatic venous blood samples were collected alternately at intervals of 3 min and ICG plasma concentration was measured. If plasma concentrations of ICG changed less than 6% within the 15-min interval, steady state conditions were assumed and hepatic plasma flow was calculated.
Cardiac output (CO) was measured by the thermodilution method using an automatic device (Fischer HZV, Mod. BN 7260, Gottingen, FRG). Systemic and pulmonary artery pressures were recorded using Statham transducers.
Plasma analytical procedures
Heparinized blood 3 ml was centrifuged immediately after sampling and absorption measured photometrically at 800 nm within at least 3 h after sampling. The calibration curve consisted of concentrations of 50, 250, 750 and 1250 mg litre" 1 with an interday coefficient of variation of 4.2% (n = 10) at 50 mg litre" 1 and 3.9% (n = 10) at 1250 mg litre-1 . Plasma concentrations of methohexitone were measured by gas chromatography with alkali flame ionization detection. This was a modification of the procedure described by Le Normand and colleagues [9] . The extraction was performed according to the method of Heusler and colleagues [10] . Plasma 1 ml was mixed with internal standard (propoxate) and solvent 10 ml (ether: n-hexan: isoamylalcohol 50: 50:2). After centrifugation, the organic supernatant was evaporated to dryness under nitrogen. The residue was dissolved in ethanol 100 ul and injected into a capillary column (30 m DB-5, 0.32 mm i.d.). The temperature of the injector was 260 °C, that of the column 230 °C and of the detector, 250 °C. Helium was used as carrier with a flow rate of Smlmin"
1 . Retention times of methohexitone and internal standard were 6.25 and 11.55 min, respectively.
Limit of detection was 0.01 ug ml" 1 . Quality control was performed with standard concentrations of methohexitone 0.5, 1.0 and 5.0 ug ml" 1 in human plasma, which were added randomly to the patients' samples and prepared together. The interserial coefficient of variation was 5.4% at_ 0.5 ug ml" 1 , 7.8 % at 1.0 ug ml" 1 and 3.6 % at 5.0 ug ml" 1 (n = 10 in all cases).
Calculations
Splanchnic oxygen consumption was calculated as the product of hepatic blood flow (hepatic plasma flow/1-PCV) and arterial-hepatic venous difference in oxygen content (LEX-O 2 CON, IL).
Hepatic extraction of methohexitone was calculated as £=(AUC sn -AUC hv )/AUC lirt , where AUC^rt and AUQ, T = areas under the arterial and hepatic venous plasma concentration-time curves extrapolated to infinity, respectively. Extrapolation to infinity was performed in order to calculate total body clearance. The AUC were calculated by the iteration method with the Gauss-Newton algorithm using the PCNONLIN computer program (Statistical Consultants Inc., Lexington, Kentucky, U.S.A.). Weighting was 1/y. The extrapolated part of the AUC represented about 20 % of the total arterial and hepatic venous AUC.
Hepatic clearance of ICG at steady state was calculated as the ratio of the infusion rate to the arterial plasma concentration. Hepatic venous concentrations of ICG could always be measured above the limit of detection. Total clearance of methohexitone (C/"") was calculated as the ratio of the dose to the arterial AUC of methohexitone and hepatic plasma clearance (C/ H ) as follows: C/ H = Q HP -£, where Q H P = hepatic plasma flow and E = hepatic extraction of methohexitone.
Results are presented as median values. Statistical analysis was performed using the Friedmann test comparing results before induction of anaesthesia (MPI) with those after induction (MPII) and the results of MPII with those at sternotomy (MPIII). Significant differences were assumed at P < 0.05.
RESULTS
All patients tolerated the investigation, without complication and were discharged from hospital after 2 weeks.
Haemodynamic data are shown in table II. Before induction of anaesthesia, median heart rate (HR) was 60 beat min" 1 ; it did not change significantly during the study. Median arterial pressure (MAP) decreased by 26 % from 106 mm Hg after induction (P < 0.01) and returned to 95 mm Hg at sternotomy (P < 0.01). Cardiac output tended to decrease by 26% after induction and remained constant at sternotomy.
ICG extraction was 0.77 before induction and did not change significantly during the investigation. ICG plasma clearance did not change after induction but tended to decrease (10%) at sternotomy. The estimated hepatic plasma flow (£>H,P) was 1.28 litre min' 1 initially and did not change significantly after induction or at sternotomy. However, as expected from the results of ICG extraction and ICG clearance, <2 H .p tended to decrease by 10% at sternotomy. Hepatic blood flow (Q H ) showed similar tendencies: it represented about 40% of cardiac output initially, 53 % after induction (P > 0.05) and 41% at sternotomy. Hepatic oxygen consumption remained unchanged and was within normal physiological ranges.
Hepatic extraction of methohexitone was 0.87. Consequently, hepatic clearance of methohexitone was 1.01 litre min" 1 , closely related to hepatic plasma flow. 
DISCUSSION
This study has confirmed that methohexitone is subject to a very high hepatic extraction. Consequently, its hepatic elimination is dependent heavily on hepatic blood flow. Distribution into deep compartments, however, is relatively more important for the overall disposition of methohexitone than its clearance by the liver. As a result, the potential for drug accumulation after repeated or continuous dosing cannot be disregarded. These conclusions, however, must be viewed in the light of the limitations of the study. For exact measurements of hepatic plasma flow, an accurate steady state must be achieved-that is, the infusion rate of the indicator and removal by the liver have to be equal. In our study, plasma concentrations remained relatively stable ( + 6%) during measurement of hepatic plasma flow, so correct steady state conditions can be assumed. Measurement of hepatic plasma flow with ICG using liver vein catheterization requires a hepatic extraction of more than 0.2 to give valid results [11] . This condition was fulfilled in our study. ICG is removed from the plasma by uptake into the hepatocyte and eliminated unchanged by canalicular excretion with the bile. Therefore, metabolic interactions between ICG and methohexitone may reasonably be excluded. External influences on haemodynamic variables also must be considered after induction of anaesthesia. Preoperative sympathetic cardiovascular responses are likely to be unimportant in our study because of effective premedication, although they cannot be excluded. All patients reached the operation area asleep and tolerated preoperative manipulations before induction of anaesthesia, including catheterization under local anaesthesia without significant cardiovascular reactions. The fact that hepatic blood flow was 40-50 % of cardiac output indicates also pronounced parasympathetic activity in the absence of stress. Interference by ICG could be excluded also, as there is no evidence for direct cardiovascular effects of ICG, which is used widely for the measurement of cardiac output and hepatic plasma flow [8, 11] .
To our knowledge, the contribution of the liver to the total clearance of methohexitone has not yet been reported. Richter and colleagues [6] reported a hepatic extraction of 0.67 for methohexitone. This difference from the value of 0.87 in our study can be explained by the limits of the method used by Richter's group, who investigated hepatic extraction by comparing parenteral and enteral methohexitone. This study design is limited by variations in intestinal absorption. Direct measurement of hepatic venous concentration of the drug, as performed in our study, is more reliable. Interactions in the elimination of methohexitone with intercurrent therapy are probably not important in our study. The therapy was discontinued the day before operation, so most of the drugs were eliminated by the day of investigation. No patient needed antianginal therapy in the period between stopping intercurrent therapy and beginning of anaesthesia. Finally, a theoretically possible interaction of elimination of methohexitone would lead to an underestimation of the extraction in our study, which would not affect our conclusions. Total body clearance of methohexitone has been described by many authors; absolute values range between 818 and 910mlmin-x [5] [6] [7] . Calculated total body clearance of methohexitone in our study was 1.28 litre min" 1 . This difference can be explained by the calculation of clearance from the area under the plasma concentration-time curve (AUC) extrapolated to infinity. As a consequence of cardiothoracic surgery, the time of sampling was limited to about 80 min after induction of anaesthesia. Extracorporeal circulation leads to rapid haemodilution. This relatively short interval for the definition of the terminal phase of the plasma concentration-time curve results in a relevant error in the definition of the slope of the P-phase, underestimating the AUC extrapolated to infinity; this leads to overestimation of total body clearance. The data in the literature are based upon sampling intervals of more than 12 h, allowing a better definition of the terminal part of the plasma concentration-time curve. In the calculation of hepatic extraction, however, the error in the definition of the AUC is eliminated, because the amount of the area extrapolated to infinity is about 20% in both arterial and hepatic venous samples. We found hepatic blood flow represented 40-50% of cardiac output (table III) . Normally, hepatic blood flow is only 20-30 % of cardiac output. Thus hepatic clearance of methohexitone might be reduced under normal conditions. This reduced value of hepatic methohexitone clearance corresponds also with the data for total body methohexitone clearance reported in the literature. It can be concluded that the liver is the only organ responsible for the elimination of methohexitone in man.
The cardiovascular effects of methohexitone found in this study are compatible with the results obtained by other investigators [12] [13] [14] . Hepatic plasma flow remained unchanged after induction with methohexitone, as did splanchnic oxygen consumption. These effects may be the result of a pronounced parasympathetic activity after effective_premedi-
